9527 Fair Value & Analysis
Healthcare · Market cap 496M SAR
Fair value as of: Jul 31, 2026
From 15 valuation models · updated today
Share price −2.2% over the past month.
Price vs Fair Value (12 months)
12‑month range 68.99 SAR – 136.22 SAR · fair‑value band 64.27 SAR – 108.77 SAR · the 70.90 SAR price screens below the 86.52 SAR fair value. As of Jul 31, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
9527 (9527) currently trades at 70.90 SAR, while our model-based Fair Value estimate is 86.52 SAR, implying the stock looks roughly 22.0% undervalued today. We read business quality at 43/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, 9527 generated revenue of 305M SAR at a net margin of 11.5%. Revenue grew 24.9% year over year. It earns a return on equity of 20.7%. Net debt stands at 17.3M SAR. Fundamentals as of Jul 31, 2026
Our scenario range runs from 64.27 SAR (bear case) to 108.77 SAR (bull case); at 70.90 SAR, the current price sits within that range. The share trades about 48% below its 52-week high and 4% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 24% fair-value upside, at 22%, 9527 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.
Quality Score breakdown
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
9527 reported revenue of 305M SAR in FY2025 versus 151M SAR in FY2021, a compound +19.1%/yr. Reported net income was 35.0M SAR in FY2025, compounding +13.3%/yr from FY2021.
Is 9527 fairly valued? → Check now
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation M1CK34 | R$999.49 | R$1,236 | +24% |
| Cencora, Inc COR | $270.32 | $168.24 | -38% |
| Cardinal Health, Inc CAH | $201.74 | $92.07 | -54% |
| Sigma Healthcare Limited SIGGF | $2.15 | $0.6400 | -70% |
| Henry Schein, Inc HSIC | $78.85 | $62.37 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.34 | ¥34.72 | +112% |
| Sinopharm Group SHTDY | $10.50 | $28.00 | +167% |
| Galenica AG GALNF | $115.00 | $98.28 | -15% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.26 | ¥30.70 | +44% |
| Medipal Holdings MEPDF | $18.35 | $28.52 | +55% |
Compare 9527 with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is 9527 overvalued or undervalued?
What is the fair value of 9527?
What is the quality score of 9527?
What is the revenue of 9527?
What is the net profit margin of 9527?
Does 9527 pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track 9527 and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.